College of Pharmacy

Print Friendly

Shufeng Zhou, Professor

Chair, Cop Dept Of Pharmaceutical Science

Chair & Professor, Cop Dept Of Pharmaceutical Science

Professor, College Of Medicine Internal Medicine

Professor, College Of Medicine Molecular Medicine

Professor, College Of Medicine Molecular Pharmacology & Physiology

Professor, Associate Vice President of Global Medical Development, Dept. of Pharmaceutical Sciences, College of Pharmacy, University of South Florida

Contact Info 12901 Bruce B Downs Blvd.,
MDC 30
Tampa, FL 33612

Academic Email:

Academic Phone: (813) 974-6276


  • PhD, Pharmacology, The University of Auckland, 2002
  • PhD, Pharmacology, University Of Auckland, 2001
  • Postgraduate Diploma, Oncology, Sun Yat-sen Medical University, 1989
  • MD, Medicine, Jiangxi Medical College, 1986

Interdisciplinary and Emerging Signature Programs

  • Allergy, Immunology & Infectious Disease
  • Biomedical Engineering & Nanomedicine
  • Cancer Biology

Research Interests

  • Dr Zhou is presently a Professor, Associate Vice President of Global Medical Development, Associate Dean of International Research, and Chair of the Department of Pharmaceutical Sciences, College of Pharmacy & Morsani College of Medicine, University of South Florida, Tampa, Florida 33612. Professor Zhou completed his clinical medical training in China in 1989 and obtained his PhD in 2001 from the Faculty of Medicine and Health Sciences, the University of Auckland, Auckland, New Zealand. He continued his postdoctoral training at the University of Auckland until November 2002. Since 2002, Dr Zhou has served as a faculty member for the National University of Singapore, Queensland University of Technology (Australia), RMIT University (Australia), and now University of South Florida. Dr Zhou’s major research interests are drug discovery/systems pharmacology, drug metabolism/drug transport & pharmacokinetics, pharmacogenomics/pharmacogenetics, nanomedicine and Chinese medicine. Professor Zhou has published more than 330 peer-reviewed papers in various pharmacology and medical journals including New England Journal of Medicine, Cancer Research, Journal of Biological Chemistry, Clinical Pharmacology and Therapeutics, Carcinogenesis, JPET, Drug Metabolism & Disposition, and Clinical Cancer Research. He has also published 16 books and book chapters and more than 310 conference abstracts. His work has been cited more than 8,600 times by other colleagues with a H-index of 46. He has received more than US$22.0 million grants from various funding bodies and industries. To date, he has trained 24 PhD students, 12 MSc/Honors students, 14 postdoctoral fellows and 25 visiting faculty. Dr Zhou serves as an editor-in-chief or editor for 16 journals including Drug, Healthcare and Patient Safety, Drug Metabolism Letters, and Current Drug Metabolism and is the editorial board member of more than 50 medical and pharmacological journals. Dr Zhou has given more than 100 invited seminars/keynote presentations to a variety of academic institutes, government agencies, and high-profile international conferences. He is a recipient of several teaching and research awards, a member of numerous national and international professional societies, and a visiting professor of many reputable research universities.

Recent Publications

  • Zhou, S.Li, Y.Kestell, P.Schafer, P.Chan, E.Paxton, JW. Transport of thalidomide by the human intestinal caco-2 monolayers. European journal of drug metabolism and pharmacokinetics. 30(1-2) : 49-61
  • Wang, G.Wen, J.Wilbur, RR.Wen, P.Zhou, SF.Xiao, X. The Effect of Somatostatin, Ulinastatin and Salvia miltiorrhiza on Severe Acute Pancreatitis Treatment. The American journal of the medical sciences. , 2013.
  • Nabar, NR.Yuan, F.Lin, X.Wang, L.Bai, G.Mayl, J.Li, Y.Zhou, SF.Wang, J.Cai, J.Cao, C. Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice. PloS one. 7(12) : e49468, 2012.
  • Mo, SL.Liu, WF.Chen, Y.Luo, HB.Sun, LB.Chen, XW.Zhou, ZW.Sneed, KB.Li, CG.Du, YM.Liang, J.Zhou, SF. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap). Combinatorial chemistry & high throughput screening. 15(1) : 36-80, 2012.
  • Yau, WP.Vathsala, A.Lou, HX.Zhou, SF.Chan, E. Simple reversed-phase liquid chromatographic assay for simultaneous quantification of free mycophenolic acid and its glucuronide metabolite in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 846(1-2) : 313-8, 2007.
  • Zhu, Y.Smith, D.Verma, C.Lim, WG.Tan, BJ.Armstrong, JS.Zhou, S.Chan, E.Tan, SL.Zhu, YZ.Cheung, NS.Duan, W. The very C-terminus of protein kinase Cepsilon is critical for the full catalytic competence but its hydrophobic motif is dispensable for the interaction with 3-phosphoinositide-dependent kinase-1. Cellular signalling. 18(6) : 807-18, 2006.
  • Koh, HL.Wang, H.Zhou, S.Chan, E.Woo, SO. Detection of aristolochic acid I, tetrandrine and fangchinoline in medicinal plants by high performance liquid chromatography and liquid chromatography/mass spectrometry. Journal of pharmaceutical and biomedical analysis. 40(3) : 653-61, 2006.
  • Yang, XX.Hu, ZP.Chan, SY.Zhou, SF. Monitoring drug-protein interaction. Clinica chimica acta; international journal of clinical chemistry. 365(1-2) : 9-29, 2006.
  • Yang, XX.Hu, ZP.Xu, AL.Duan, W.Zhu, YZ.Huang, M.Sheu, FS.Zhang, Q.Bian, JS.Chan, E.Li, X.Wang, JC.Zhou, SF. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. The Journal of pharmacology and experimental therapeutics. 319(1) : 82-104, 2006.
  • Yeong, SS.Zhu, Y.Smith, D.Verma, C.Lim, WG.Tan, BJ.Li, QT.Cheung, NS.Cai, M.Zhu, YZ.Zhou, SF.Tan, SL.Duan, W. The last 10 amino acid residues beyond the hydrophobic motif are critical for the catalytic competence and function of protein kinase Calpha. The Journal of biological chemistry. 281(41) : 30768-81, 2006.
  • Zhang, J.Tian, Q.Zhu, YZ.Xu, AL.Zhou, SF. Reversal of resistance to oxazaphosphorines. Current cancer drug targets. 6(5) : 385-407, 2006.
  • Yang, XX.Hu, ZP.Chan, E.Duan, W.Zhou, S. Pharmacokinetics of recombinant human endostatin in rats. Current drug metabolism. 7(6) : 565-76, 2006.
  • Hu, ZP.Yang, XX.Chan, SY.Xu, AL.Duan, W.Zhu, YZ.Sheu, FS.Boelsterli, UA.Chan, E.Zhang, Q.Wang, JC.Ee, PL.Koh, HL.Huang, M.Zhou, SF. St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicology and applied pharmacology. 216(2) : 225-37, 2006.
  • Yang, XX.Hu, ZP.Duan, W.Zhu, YZ.Zhou, SF. Drug-herb interactions: eliminating toxicity with hard drug design. Current pharmaceutical design. 12(35) : 4649-64, 2006.
  • Zhou, S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Current clinical pharmacology. 1(1) : 119-28, 2006.
  • Yang, X.Hu, Z.Chan, SY.Ho, PC.Chan, E.Duan, W.Goh, BC.Zhou, S. Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. Journal of pharmaceutical and biomedical analysis. 39(1-2) : 299-304, 2005.
  • Hu, Z.Yang, X.Ho, PC.Chan, E.Chan, SY.Xu, C.Li, X.Zhu, YZ.Duan, W.Chen, X.Huang, M.Yang, H.Zhou, S. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharmaceutical research. 22(6) : 902-14, 2005.
  • Yang, X.Hu, Z.Chan, SY.Goh, BC.Duan, W.Chan, E.Zhou, S. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 821(2) : 221-8, 2005.
  • Zhu, Y.Dong, Q.Tan, BJ.Lim, WG.Zhou, S.Duan, W. The PKCalpha-D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals. Cancer research. 65(11) : 4520-4, 2005.
  • Hu, Z.Yang, X.Ho, PC.Chan, SY.Heng, PW.Chan, E.Duan, W.Koh, HL.Zhou, S. Herb-drug interactions: a literature review. Drugs. 65(9) : 1239-82, 2005.
  • Zhou, Q.Zhou, S.Chan, E. Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes. Current drug metabolism. 6(2) : 67-81, 2005.
  • Li, J.Zhou, S.Huynh, H.Chan, E. Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. Pharmaceutical research. 22(3) : 397-404, 2005.
  • Yang, X.Hu, Z.Chan, SY.Chan, E.Goh, BC.Duan, W.Zhou, S. Novel agents that potentially inhibit irinotecan-induced diarrhea. Current medicinal chemistry. 12(11) : 1343-58, 2005.
  • Paxton, JW.Kestell, P.Chiang, D.Zhou, S.Lewis, DF. Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study. Clinical and experimental pharmacology & physiology. 32(8) : 633-9, 2005.
  • Zhang, J.Tian, Q.Yung Chan, S.Chuen Li, S.Zhou, S.Duan, W.Zhu, YZ. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug metabolism reviews. 37(4) : 611-703, 2005.
  • Zhou, S.Huang, M.Xu, A.Yang, H.Duan, W.Paxton, JW. Prediction of herb-drug metabolic interactions: a simulation study. Phytotherapy research : PTR. 19(6) : 464-71, 2005.
  • Zhang, J.Tian, Q.Chan, SY.Duan, W.Zhou, S. Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 8(5) : 271-97, 2005.
  • Tian, Q.Zhang, J.Tan, TM.Chan, E.Duan, W.Chan, SY.Boelsterli, UA.Ho, PC.Yang, H.Bian, JS.Huang, M.Zhu, YZ.Xiong, W.Li, X.Zhou, S. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharmaceutical research. 22(11) : 1837-53, 2005.
  • Zhou, Q.Zhou, S.Chan, E. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Current drug metabolism. 6(5) : 399-411, 2005.
  • Li, J.Zhou, S.Huynh, H.Duan, W.Chan, E. Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin. Pharmaceutical research. 22(11) : 1954-63, 2005.
  • Zhou, S.Chan, E.Duan, W.Huang, M.Chen, YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug metabolism reviews. 37(1) : 41-213, 2005.
  • Zhou, S.Yung Chan, S.Cher Goh, B.Chan, E.Duan, W.Huang, M.McLeod, HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clinical pharmacokinetics. 44(3) : 279-304, 2005.
  • Zhou, S.Feng, X.Kestell, P.Paxton, JW.Baguley, BC.Chan, E. Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 24(5) : 513-24, 2005.
  • Zhou, S.Chan, E.Pan, SQ.Huang, M.Lee, EJ. Pharmacokinetic interactions of drugs with St John's wort. Journal of psychopharmacology (Oxford, England). 18(2) : 262-76, 2004.
  • Zhou, S.Chan, E.Lim, LY.Boelsterli, UA.Li, SC.Wang, J.Zhang, Q.Huang, M.Xu, A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Current drug metabolism. 5(5) : 415-42, 2004.
  • Zhou, S.Lim, LY.Chowbay, B. Herbal modulation of P-glycoprotein. Drug metabolism reviews. 36(1) : 57-104, 2004.
  • Zhou, S.Feng, X.Kestell, P.Baguley, BC.Paxton, JW. Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 809(1) : 87-97, 2004.
  • Zhou, S.Koh, HL.Gao, Y.Gong, ZY.Lee, EJ. Herbal bioactivation: the good, the bad and the ugly. Life sciences. 74(8) : 935-68, 2004.
  • Zhou, S.Chan, E.Li, SC.Huang, M.Chen, X.Li, X.Zhang, Q.Paxton, JW. Predicting pharmacokinetic herb-drug interactions. Drug metabolism and drug interactions. 20(3) : 143-58, 2004.
  • Zhou, S.Kestell, P.Baguley, BC.Paxton, JW. Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical pharmacology. 65(11) : 1853-65, 2003.
  • Zhou, S.Kestell, P.Baguley, BC.Paxton, JW. Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical pharmacology. 65(1) : 109-20, 2003.
  • Zhou, S.Li, Y.Kestell, P.Paxton, JW. Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 785(1) : 165-73, 2003.
  • Zhou, S. Separation and detection methods for covalent drug-protein adducts. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 797(1-2) : 63-90, 2003.
  • Zhou, S.Gao, Y.Jiang, W.Huang, M.Xu, A.Paxton, JW. Interactions of herbs with cytochrome P450. Drug metabolism reviews. 35(1) : 35-98, 2003.
  • Zhou, S.Kestell, P.Tingle, MD.Paxton, JW. Thalidomide in cancer treatment: a potential role in the elderly? Drugs & aging. 19(2) : 85-100, 2002.
  • Zhou, S.Kestell, P.Paxton, JW. Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species. The Journal of pharmacy and pharmacology. 54(7) : 997-1003, 2002.
  • Zhou, S.Kestell, P.Paxton, JW. Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 776(2) : 231-6, 2002.
  • Zhou, S.Kestell, P.Paxton, JW. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug metabolism reviews. 34(4) : 751-90, 2002.
  • Zhou, S.Kestell, P.Tingle, MD.Ching, LM.Paxton, JW. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide. Cancer chemotherapy and pharmacology. 47(6) : 541-4, 2001.
  • Zhou, S.Chin, R.Kestell, P.Tingle, MD.Paxton, JW. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. British journal of clinical pharmacology. 52(2) : 129-36, 2001.
  • Zhou, S.Paxton, JW.Tingle, MD.Kestell, P. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug metabolism and disposition: the biological fate of chemicals. 28(12) : 1449-56, 2000.

Positions Held

  • Associate Professor (School of Health Sciences, RMIT University 2007 - 2010)
  • Senior Lecturer (School of Pharmacy, Queensland University of Technology 2007 - 2007)
  • Assistant Professor (Dept. of Pharmacy, National University of Singapore 2002 - 2006)
  • Posdoctoral Research Fellow (Faculty of Medicine & Health Sciences, The University of Auckland 2001 - 2002)
  • Physician and Specialist in GI (Dept. of Internal Medicine, Guangzhou Medical College, Guangzhou First People's Hospital 1989 - 1995)